Molecular Partners Ag Stock Cash Per Share
| MOLN Stock | CHF 5.20 0.10 1.96% |
Molecular Partners AG fundamentals help investors to digest information that contributes to Molecular Partners' financial success or failures. It also enables traders to predict the movement of Molecular Stock. The fundamental analysis module provides a way to measure Molecular Partners' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Molecular Partners stock.
Molecular |
Molecular Partners AG Company Cash Per Share Analysis
Molecular Partners' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Molecular Partners Cash Per Share | 8.22 X |
Most of Molecular Partners' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Molecular Partners AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, Molecular Partners AG has a Cash Per Share of 8.22 times. This is 88.97% higher than that of the Healthcare sector and 89.84% higher than that of the Biotechnology industry. The cash per share for all Switzerland stocks is 64.07% lower than that of the firm.
Molecular Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Molecular Partners' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Molecular Partners could also be used in its relative valuation, which is a method of valuing Molecular Partners by comparing valuation metrics of similar companies.Molecular Partners is currently under evaluation in cash per share category among its peers.
Molecular Fundamentals
| Return On Equity | 0.62 | |||
| Return On Asset | 0.32 | |||
| Profit Margin | 0.62 % | |||
| Operating Margin | 0.61 % | |||
| Current Valuation | (39.23 M) | |||
| Shares Outstanding | 36.04 M | |||
| Shares Owned By Insiders | 14.13 % | |||
| Shares Owned By Institutions | 45.01 % | |||
| Price To Earning | 2.02 X | |||
| Price To Book | 0.89 X | |||
| Price To Sales | 1.19 X | |||
| Revenue | 9.33 M | |||
| Gross Profit | (45.96 M) | |||
| EBITDA | (60.67 M) | |||
| Net Income | (63.78 M) | |||
| Cash And Equivalents | 267.13 M | |||
| Cash Per Share | 8.22 X | |||
| Total Debt | 4.85 M | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 14.37 X | |||
| Book Value Per Share | 7.73 X | |||
| Cash Flow From Operations | (90.95 M) | |||
| Earnings Per Share | 3.53 X | |||
| Target Price | 13.98 | |||
| Number Of Employees | 163 | |||
| Beta | 0.62 | |||
| Market Capitalization | 215.91 M | |||
| Total Asset | 172.67 M | |||
| Z Score | 26.4 | |||
| Net Asset | 172.67 M |
About Molecular Partners Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Molecular Partners AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Molecular Partners using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Molecular Partners AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Molecular Stock Analysis
When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.